Brief: Alligator Announces Final 30-Month Optimize-1 Results
22/09/2025 07:45
Sept 22 (Reuters) - Alligator Bioscience AB ATORX.ST: ALLIGATOR ANNOUNCES FINAL 30-MONTH OPTIMIZE-1 RESULTS HIGHLIGHTING THE POTENTIAL OF MITAZALIMAB IN METASTATIC PANCREATIC CANCER Source text: ID:nMFN5FFLqB Further company coverage: ATORX.ST (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln